References
- Hanks G E, Schultheiss T E, Hunt M A, Epstein B. Factors influencing incidence of acute grade II morbidity in conformal and standard radiation treatment of prostate cancer. Int J Radiat Oncol Biol Phys, (in press)
- Vijayakumar S, Awan A, Karrison T. Acute toxicity during external-beam radiotherapy for localized prostate cancer: Comparison of different techniques. Int J Radiat Oncol Biol Phys 1993; 25: 359–371
- Sandler H, Perez- M., Tamayo C, Ten-Haken R K. Dose escalation for stage C (T3) prostate cancer: Minimal rectal toxicity observed using conformal therapy. Radiother Oncol 1992; 23: 53–54
- Corn B W, Hanks G E. Superior PSA response achieved with conformal radiation therapy of prostate cancer. Int J Radiat Oncol Biol Phys, (in press)
- Soloway M. Principal Investigator: T-2B presurgery cytoreduction study
- Pilepich M V, Krall J M, Al-Sarraf M. A phase III trial of androgen suppression before and during radiation therapy (RT) for locally advanced prostatic carcinoma: Preliminary report of RTOG protocol #86–10. J Clin Oncol 1993; 12: 229
- MacFarlane M, Abi- T., Aad A, Stein A. Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer. J Urol 1992; 147: 246
- Tunn U W, Goldschmidt A, Steigenwald S. Efficacy of neoadjuvant antiandrogenic treatment prior to radical prostatectomy. J Urol 1992; 147: 246